Natco Pharma NPPA notice: ₹4.92 crore demand (2026)

What Natco Pharma disclosed to exchanges

NATCO Pharma Limited has disclosed that it received a demand notice from the National Pharmaceutical Pricing Authority (NPPA), New Delhi. The notice is dated 12 May 2026, and the company also recorded the date of receipt as 12 May 2026. The demand directs NATCO Pharma to deposit a total of ₹4,92,25,923. The company said the amount includes the overcharge amount, penalty, and interest. The notice relates to alleged overcharging involving two drugs. The period cited in the notice covers April 2023 to November 2023. In its communication, NATCO Pharma stated that the notice has no material impact on its financial, operational, or other activities.

Timeline: notice date, receipt, and updated filing

The NPPA demand notice is dated 12 May 2026 and was received on the same day, according to the company’s disclosure. NATCO Pharma later made an updated filing on 15 May 2026. In that updated filing, the company disclosed that there was a delay in its initial submission. It attributed the delay to technical and procedural issues. The company also reiterated that it does not expect a material impact on financial or operational activities. The filings place the regulatory action and the company’s response within the same week. There was no additional detail provided in the shared text on whether NATCO Pharma plans to contest the demand, seek a review, or deposit the amount.

What the demand notice alleges

The notice alleges overcharging for two drugs. The period of alleged overcharging is stated as April 2023 to November 2023. The demand has been issued under paragraph 15 of the Drugs Price Control Order, 2013 (DPCO). The amount sought is ₹4,92,25,923, which equals about ₹4.92 crore when expressed in crore terms. The figure explicitly includes overcharge, penalty, and interest. The disclosure does not provide product names, the computation method, or the breakup across the three components. It also does not specify the volume of sales or the price ceilings involved.

Regulatory context: DPCO 2013 and NPPA actions

The NPPA is the authority referenced in the disclosure, and the notice is described as a demand notice under para 15 of DPCO 2013. The DPCO framework is used for price control and related compliance in pharmaceuticals in India. In this case, the company’s filing positions the action as a specific allegation limited to two drugs and a defined historical period. The disclosure focuses on compliance reporting and the demand amount, rather than broader regulatory commentary. There is no statement in the provided text on any parallel inspections, audits, or additional notices. The company’s key emphasis remains on the absence of material impact on operations and finances.

Company statement on business impact

NATCO Pharma has stated that the demand notice has no material impact on the financial, operational, or other activities of the company. This is the central business implication presented in the filing. The company did not provide quantified sensitivity, provisioning, or cash-flow detail in the provided extract. It also did not link the notice to any specific business segment or geography. The statement suggests that, at least as per the company’s current assessment, the demand amount is not expected to disrupt day-to-day operations. The company’s clarification on the filing delay also indicates it wanted the market to understand the timing of its disclosure.

Key facts at a glance

Market references and upcoming events disclosed

The provided information also mentions the current price of Natco Pharma Ltd as ₹843.25. No date or timestamp is provided alongside that price point in the shared text, so readers should treat it as a referenced snapshot rather than a specific close. Separately, NATCO Pharma is scheduled to attend an investor meeting on 7 September 2026 in Hyderabad. The company has also informed BSE that a meeting of its Board of Directors is scheduled on 14 August 2026 to consider and evaluate proposals for raising funds through the issuance of equity, as per the text provided. These events are distinct from the NPPA notice, but they form part of the broader disclosure flow around the company.

Other corporate updates mentioned alongside the notice

The shared text also states that NATCO Pharma Limited completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited. No completion date, transaction value, or funding method is included in the provided extract. In addition, NATCO’s Specialty division is described as handling therapy segments including Gastroenterology or Hepatology, Orthopedic or Rheumatology, Neurology, and Infectious Diseases or HIV. These details help frame NATCO’s operating footprint but do not change the narrow allegation described in the NPPA demand. The text also lists investor contact emails: investors@natcopharma.co.in and ir@natcopharma.co.in. The corporate address mentioned is Natco House, Road# 2, Banjara Hills, Hyderabad - 500 034.

Event calendar items in the provided data

Why the disclosure matters for investors

The disclosure is significant because it quantifies a regulatory demand and specifies the statutory basis cited in the notice. It also narrows the allegation to two drugs and a defined period between April and November 2023. For investors, the immediate information available is the demanded amount and the company’s statement that there is no material impact on its financial or operational activities. The updated filing on 15 May 2026 adds process detail by explaining the delay as technical and procedural. Beyond those points, the provided text does not include management commentary on next steps. Any further clarity is likely to come only through subsequent exchange filings or formal communication from the company or regulator.

Conclusion

NATCO Pharma’s filing reports an NPPA demand notice dated and received on 12 May 2026, seeking ₹4,92,25,923 for alleged overcharging of two drugs during April to November 2023. In its updated 15 May 2026 filing, the company cited technical and procedural issues for a disclosure delay and reiterated that it expects no material impact on operations or finances. Separate from the notice, the company has upcoming engagements including a board meeting on 14 August 2026 and an investor meeting on 7 September 2026 in Hyderabad. Any change in the company’s stance or financial treatment of the demand would need to be tracked through future regulatory filings.